Breaking the Barrier: Challenges in Hepatitis B Seroprotection Among Dialysis Patients
DOI:
https://doi.org/10.53778/pjkd84285Keywords:
Hemodialysis, cross infection, Hepatitis B virus, Hepatitis C Virus, immunization, anti HBs, HBsAg, seroconversionAbstract
The high prevalence of hepatitis B and C in the dialysis population is a significant concern in resource-limited settings. While advances in Hepatitis C treatment have mitigated its severity, Hepatitis B remains a critical challenge despite the availability of vaccination.
Methods:
A retrospective review of hemodialysis data was conducted to assess seroconversion rates in patients vaccinated against Hepatitis B. All unvaccinated patients initiating hemodialysis were vaccinated using a modified-accelerated schedule of 40 µg inactivated HBsAg (Engerix B) on days 0, 7, 21, and 180 as per institutional policy. Anti-HBs levels >10 mIU/mL were considered indicative of seroprotection.
Results: Of the 39 patients with complete data (out of 86), 16 (41%) were negative for Anti-HBs. The mean Anti-HBs level in positive patients was 275 IU/L (±353.98), while it was 2.77 IU/L (±2.71) in negative patients.
Conclusion: Despite adherence to a super-accelerated vaccination protocol, a significant proportion of dialysis patients fail to achieve protective Anti-HBs levels, underscoring the need for tailored vaccination strategies and regular monitoring in this vulnerable population.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Kidney Diseases

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.